HALBERD CORP - HALB STOCK NEWS

Halberd Corporation (OTC PINK: HALB) CEO William A. Hartman discussed recent achievements and strategic initiatives in an interview on Money TV. Halberd has partnered with Arizona State University for research and is focused on developing Covid-19 antibodies and related technologies. The company has filed provisional patents for innovative treatments and maintains a debt-free status. Hartman also highlighted potential applications for their technology in various diseases and introduced a prototype for an Anti-Addiction Patch. Halberd aims for significant market success amidst the ongoing pandemic challenges.

Halberd Corporation (OTC PINK: HALB) has announced the development of a new class of anti-Spike protein monoclonal antibodies targeting Covid-19, in collaboration with Arizona State University. They are in the process of filing joint patent applications for this discovery. The engineered antibodies may enable rapid detection of the virus in various samples and on surfaces. This advancement aims to enhance early identification and treatment, potentially curbing the virus's spread. Halberd's CTO highlighted the progress, signaling more patent applications to follow.

Halberd Corporation (OTC PINK: HALB) announced significant advancements in COVID-19 research through collaboration with Arizona State University. Researchers have successfully produced an anti-Spike protein monoclonal antibody targeting the virus, with plans for patent protections. Potential applications include a preventative, diagnostic, and therapeutic treatment. The company aims to provide ongoing updates on the progress of this vital research.

Halberd Corporation (OTC PINK: HALB) has made significant strides since May, focusing on coronavirus detection and treatment. Key achievements include recruiting top talent, securing exclusive licenses for four provisional patents related to COVID-19, and establishing a partnership with a leading university for research. Plans for the upcoming quarter involve in-depth testing of a novel COVID antibody for preventative, diagnostic, and therapeutic purposes. Halberd emphasizes the importance of collaborations with established pharmaceutical firms to expedite product development and FDA certification.

Halberd Corporation (OTC PINK: HALB) has secured a worldwide license for a provisional patent on a nasal spray aimed at preventing the transmission of coronavirus. The spray utilizes an antibody solution to block ACE2 receptors in nasal epithelial cells, potentially reducing the severity of COVID-19. This invention encompasses a protective measure against coronaviruses and aligns with Halberd's ongoing research in combating COVID-19. The company holds exclusive rights to several related patents, enhancing its position in the market for COVID-19 treatments.

Halberd Corporation (OTC PINK: HALB) has obtained exclusive rights to a provisional patent for a nasal spray aimed at preventing COVID-19 transmission. This development is based on research indicating that children have fewer ACE2 receptors, which the virus uses to infect cells. Halberd, in collaboration with Arizona State University, is pursuing a comprehensive approach involving a preventative nasal spray, fast diagnostics, and therapeutic treatments. The company is ready to initiate testing in South America and is seeking partners for pharmaceutical development.

Halberd Corporation (OTC PINK: HALB) has announced a collaborative research project with Arizona State University to develop a rapid diagnostic test for Covid-19. The focus is on the coronavirus spike antigen, which is critical to the virus's contagiousness. Feasibility samples of an antibody conjugate are expected in four weeks, potentially enabling a quick testing method using saliva or blood. The company holds exclusive rights to relevant provisional patents for Covid-19 treatments.

Halberd Corporation (OTC PINK: HALB) announced a significant breakthrough in its COVID-19 research project with Arizona State University. Dr. Qiang Chen's team successfully recreated the coronavirus spike protein disease antigen, paving the way for the identification of proprietary antibodies expected within two weeks. The joint efforts aim to secure patent protections for their findings. The company's patented extracorporeal process could improve detection and treatment of COVID-19 while minimizing side effects associated with traditional drug therapies.

Halberd Corporation (OTC PINK: HALB) has outlined the second stage goals of its $1.4 million partnership with Arizona State University. This stage focuses on utilizing a dialysis method to identify Covid-19 samples through the removal of fluorescent antibody-antigen complexes. Initial findings from the first phase are promising, with results expected soon. Halberd's technology aims to enhance diagnosis and treatment of Covid-19, with multiple methods under investigation for optimal effectiveness. The company remains debt-free and compliant with OTC reporting requirements.